Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis

Authors


Manuela Födinger, MD, Department of Laboratory Medicine, Division of Endocrinology and Metabolism, University of Vienna, Währinger Gürtel 18–20, A-1090 Wien, Austria. E-mail: manuela.foedinger@akh-wien.ac.at

Abstract

The proto-oncogene C-KIT encodes a tyrosine kinase receptor that is expressed on mast cells and haematopoietic stem cells and can show somatic mutations in patients with mastocytosis. Only scattered information is available about mutations in C-KIT in patients with other myeloid neoplasms. Moreover, the prevalence of mutations in C-KIT in bone marrow specimens of individuals with systemic mastocytosis is largely unknown. Using sequence analysis, we have screened cDNAs of the C-KIT domain encompassing codon 510–626 and codon 763–858 in bone marrow (BM) mononuclear cells (MNCs) of patients with myelodysplastic syndromes (n = 28) and patients with systemic mastocytosis (n = 12) for the presence of mutations. Furthermore, restriction fragment length polymorphism analysis was applied for identification of the C-KIT 2468A→T and the C-KIT 1700T→G mutation, as well as the C-KIT 1642A→C polymorphism. All 11 patients with systemic indolent mastocytosis tested positive for C-KIT 2468A→T. In contrast, no mutation was identified in the case of aggressive mastocytosis. Among patients with myelodysplastic syndromes, no patient showed a somatic mutation in C-KIT. The allele frequency for C-KIT 1642A→C among the entire patient population was 0·038 and was 0·125 among age- and sex-matched healthy controls. Our data demonstrate that myelodysplastic syndromes without histological or cytological evidence of mastocytosis do not exhibit somatic mutations in exons 10, 11, 12, 16, 17 and 18 of C-KIT. In contrast, BM MNCs of patients with systemic indolent mastocytosis were all positive for C-KIT 2468A→T and negative for additional mutations in these exons. The C-KIT 1642A→C polymorphism is not associated with myelodysplastic syndrome or systemic mastocytosis.

Ancillary